Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer

人类癌症中 STAG2 失活和非整倍性分析

基本信息

  • 批准号:
    8501829
  • 负责人:
  • 金额:
    $ 32.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-03-07 至 2018-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): One of the most common features that distinguishes cancer cells from normal cells is the presence of aneuploidy. We have recently discovered a cause of aneuploidy in a substantial fraction of malignant human tumors - deletions, somatic mutations, and loss of expression of the STAG2 gene (Science 336:1039-1043, 2011). The encoded STAG2 protein is a key component of the multi-protein cohesin complex which regulates sister chromatid cohesion and helps ensure faithful chromosome segregation during mitosis. In this grant we propose a multi-faceted effort to further define the mechanism through which STAG2 inactivation leads to chromosomal instability, aneuploidy, and cancer. In Aim #1 we will evaluate the effects of tumor-derived mutations in STAG2 on sister chromatid cohesion and protein-protein interactions. The goal is to functionally evaluate mutations in STAG2 to reveal the key activities of STAG2 that are lost during tumorigenesis. In Aim #2 we will determine the effect of STAG2 truncating mutations on the protein composition of cohesin and its ability to interact with chromatin at different phases of the cell cycle. These experiments wil enable us to identify key mechanisms by which STAG2 inactivation leads to chromosomal instability and aneuploidy. In Aim #3 we will determine the role of STAG2 inactivation on the initiation and maintenance of transformation in human astrocytes and GBM cells. These experiments will enable us to determine if STAG2 inactivation results in enhanced susceptibility to malignant transformation. In Aim #4 we will determine if mutations in STAG2 cause GBM cells to be sensitized to ionizing radiation and DNA damaging chemotherapeutic drugs. The broad goal of the proposed research program is to determine the mechanism through which STAG2 inactivation leads to chromosomal instability, aneuploidy, and cellular transformation, making it possible to develop strategies for identifying novel anticancer therapeutics that specifically target aneuploid cells.
描述(由申请人提供):区分癌细胞与正常细胞的最常见特征之一是存在非整倍性。我们最近发现了在相当大部分的恶性人类肿瘤中非整倍性的原因-STAG 2基因的缺失、体细胞突变和表达丧失(Science 336:1039-1043,2011)。编码的STAG 2蛋白是多蛋白粘附素复合物的关键组分,其调节姐妹染色单体的粘附并有助于确保有丝分裂期间染色体的忠实分离。在这项资助中,我们提出了一个多方面的努力,以进一步确定STAG 2失活导致染色体不稳定,非整倍性和癌症的机制。在目标#1中,我们将评估STAG 2中肿瘤源性突变对姐妹染色单体凝聚力和蛋白质-蛋白质相互作用的影响。目的是功能性地评估STAG 2中的突变,以揭示STAG 2在肿瘤发生过程中丢失的关键活性。在目标#2中,我们将确定STAG 2截短突变对粘附素的蛋白质组成及其在细胞周期的不同阶段与染色质相互作用的能力的影响。这些实验将使我们能够确定STAG 2失活导致染色体不稳定性和非整倍性的关键机制。在目标#3中,我们将确定STAG 2失活对人星形胶质细胞和GBM细胞中转化的启动和维持的作用。这些实验将使我们能够确定STAG 2失活是否导致对恶性转化的易感性增强。在目标#4中,我们将确定STAG 2中的突变是否导致GBM细胞对电离辐射和DNA损伤化疗药物敏感。拟议研究计划的广泛目标是确定STAG 2失活导致染色体不稳定性,非整倍体和细胞转化的机制,从而有可能开发用于鉴定特异性靶向非整倍体细胞的新型抗癌疗法的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TODD A WALDMAN其他文献

TODD A WALDMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TODD A WALDMAN', 18)}}的其他基金

Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer
人类癌症中 STAG2 失活和非整倍性分析
  • 批准号:
    8819107
  • 财政年份:
    2013
  • 资助金额:
    $ 32.23万
  • 项目类别:
Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer
人类癌症中 STAG2 失活和非整倍性分析
  • 批准号:
    8633441
  • 财政年份:
    2013
  • 资助金额:
    $ 32.23万
  • 项目类别:
Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer
人类癌症中 STAG2 失活和非整倍性分析
  • 批准号:
    9008028
  • 财政年份:
    2013
  • 资助金额:
    $ 32.23万
  • 项目类别:
Development and Application of Endogenous Epitope Tagging Technology in Human Cel
人细胞内源表位标记技术的开发及应用
  • 批准号:
    7777680
  • 财政年份:
    2010
  • 资助金额:
    $ 32.23万
  • 项目类别:
Development and Application of Endogenous Epitope Tagging Technology in Human Cel
人细胞内源表位标记技术的开发及应用
  • 批准号:
    8044714
  • 财政年份:
    2010
  • 资助金额:
    $ 32.23万
  • 项目类别:
A PTEN-Dependent Size Checkpoint in Human Cancer Cells
人类癌细胞中 PTEN 依赖性大小检查点
  • 批准号:
    7417921
  • 财政年份:
    2006
  • 资助金额:
    $ 32.23万
  • 项目类别:
A PTEN-Dependent Size Checkpoint in Human Cancer Cells
人类癌细胞中 PTEN 依赖性大小检查点
  • 批准号:
    7685028
  • 财政年份:
    2006
  • 资助金额:
    $ 32.23万
  • 项目类别:
A PTEN-Dependent Size Checkpoint in Human Cancer Cells
人类癌细胞中 PTEN 依赖性大小检查点
  • 批准号:
    7105903
  • 财政年份:
    2006
  • 资助金额:
    $ 32.23万
  • 项目类别:
A PTEN-dependent cell size checkpoint in human cells
人类细胞中 PTEN 依赖性细胞大小检查点
  • 批准号:
    8690786
  • 财政年份:
    2006
  • 资助金额:
    $ 32.23万
  • 项目类别:
A PTEN-dependent cell size checkpoint in human cells
人类细胞中 PTEN 依赖性细胞大小检查点
  • 批准号:
    8578465
  • 财政年份:
    2006
  • 资助金额:
    $ 32.23万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 32.23万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 32.23万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 32.23万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 32.23万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 32.23万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 32.23万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 32.23万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 32.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 32.23万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 32.23万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了